Superpower raises $30M Series A to build an AI doctor in everyone's pocket

Summary

Superpower has closed a $30 million Series A, which founder Jacob describes as the company's largest capitalization to date and, in his framing, enough to remove capital as a constraint as it scales.

The founding story is personal. In 2022, Jacob was hospitalized for close to four months after being diagnosed with Crohn's disease, underwent multiple surgeries, lost part of his stomach, and was left with a multi-million dollar bill. His read on what went wrong is structural: health systems are financially incentivized toward pharmaceuticals and surgery rather than identifying root causes. After posting about the experience on Twitter, he was connected to high-end concierge medicine practices that charge $50,000 to $100,000 a year and cater primarily to the tech billionaire class. Those practices run exhaustive testing, spend hours connecting the dots across a patient's full health picture, and assign a dedicated team to manage ongoing care. The gap between that experience and what most Americans have access to is Superpower's core pitch.

The product

Superpower is building what Jacob calls an AI doctor in everyone's pocket. The architecture aggregates a user's medical records and health data, makes comprehensive biomarker testing accessible, and layers on medical knowledge that Jacob argues does not fully exist in any single foundation model today. Current foundation models, he says, are each trained on a subset of the medical and healthcare literature, so Superpower is pulling across multiple sources to get closer to a complete picture of what is happening at the edge of science and medicine.

The regulatory constraint is real and shapes the product design. AI cannot yet make a formal medical diagnosis or recommendation under current FDA rules, so Superpower has built a human-in-the-loop model: the AI handles analysis and pattern recognition, but any point requiring a firm recommendation hands off to a physician. Jacob describes this as the industry-wide paradigm for now, and the live demo at the end of the segment shows the product querying a user's own lab results and generating personalized guidance before routing to a doctor when a recommendation would cross the regulatory line.

Lab infrastructure and the Theranos question

On the testing side, Superpower builds at the application layer and routes through commoditized lab infrastructure like LabCorp and Quest rather than attempting to own the physical lab process. Jacob sees the current testing experience — nurses visiting homes, eight or nine tubes of blood, results taking a week, a dozen friction points — as something that will improve materially over the next few years, with a legitimate Theranos-style finger-prick model potentially not far off. His lesson from Theranos is narrow: don't apply move-fast-break-things to consumer health. Healthcare requires a different standard of care than software, and the failure was one of execution and integrity, not of the underlying vision.

Go-to-market logic

Jacob's near-term distribution bet is employer benefits. Because the average American changes jobs every two to three years and health coverage is tied to the employer, insurers have no incentive to underwrite long-term preventative or optimization-focused care. That creates an opening for employers to offer Superpower-style preventative health as a supplemental benefit, both to differentiate in a competitive hiring market and to reduce long-term health costs in their workforce. Jacob sees this as an inevitable employer category, not a fringe perk.

The longer-term ambition is for a large majority of Americans to carry Superpower as their primary consumer health app, making it the dominant platform as consumer healthcare finally catches up to the reinvention that has already happened across most other industries.